Amicus Therapeutics (NASDAQ: FOLD) was upgraded by equities research analysts at JPMorgan Chase (NYSE: JPM) from a “neutral” rating to an “overweight” rating in a research note issued to investors on Tuesday.
Several other analysts have also recently commented on the stock. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of Amicus Therapeutics in a research note to investors on Thursday, February 23rd.
Shares of Amicus Therapeutics traded down 3.77% during mid-day trading on Tuesday, hitting $4.85. Amicus Therapeutics has a 52 week low of $2.10 and a 52 week high of $8.12. The company’s market cap is $168.9 million.
Amicus Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally-administered, small molecule drugs known as pharmacological chaperones.